Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
Roche received FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and measure viral load levels of COVID-19
On Jun. 15, 2022, Roche announced that the US Food and Drug Administration had issued Emergency Use Authorization…
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a booster
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
SARS-CoV-2 RNA can persist in stool months after respiratory tract clears virus
On May 18, 2022, SARS-CoV-2, or at least pieces of it, sticks around longer in some infected individuals…
Tabula Sapiens multiple-organ, single-cell transcriptomic atlas of humans published
On May 13, 2022, the Tabula Sapiens Consortium announced it had published a molecular reference atlas for more…
Moderna finalized plan for long-term strategic partnership with the Government of Canada
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
Moderna filed to expand conditional Marketing Authorization for COVID-19 vaccine to include children six months to under six years in the EU
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
CureVac and GSKﾒs bivalent second-generation mRNA accine candidate shown to be highly effective against SARS-CoV-2 variants
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
Moderna announced clinical update on bivalent COVID-19 booster platform
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
CureVac and GSK entered into Pandemic preparedness contract with German government Candidate, CV2CoV
On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German…
BioNTech granted pandemic preparedness contract by German Federal Ministry of Health
On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of…
IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
CureVac and GSK started clinical development of second-generation COVID-19 vaccine Candidate, CV2CoV
On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of…
Moderna received FDA approval for EUA of 2nd booster dose of its COVID-19 vaccine, mRNA-1273
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
Twist Bioscience launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in imagene’s stainless steel capsules
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
Moderna submited amendment to EUA for an additional booster dose of its COVID-19 vaccine in the U.S.
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
COVID-19 | HIV | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
CDC reported effectiveness of 2-Dose BNT162b2 mRNA vaccine in preventing SARS-CoV-2 infection among children
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDCﾒs Advisory Committee on Immunization…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
Moderna announced MOU with Government of Kenya to establish first mRNA manufacturing facility on the continent of Africa
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…